Novartis Collaboration and License Agreement ("the Novartis Agreement") - Performance Obligation (Details) - Novartis - Novartis Agreement, R&D For Integrin Research Targets - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01 $ in Millions	Mar. 31, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 1.2
Revenue, remaining performance obligation, expected timing of satisfaction, period	9 months